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Background: Chemotherapy-induced liver injury is a well-known phenomenon after neoadjuvant therapy of liver
metastasis and contributes to postoperative morbidity and mortality. Still there is no suitable test available to reliably
determine functional impairment and hepatic regeneration after chemotherapy.
Case presentation: We report two cases of caucasian patients who underwent repeated liver function assessments
using LiMAx (maximum liver function capacity), Indocyanine plasma disappearance rate and biochemical liver function
parameters in the course of adjuvant oxaliplatin-based chemotherapy.
Both patients yielded a decrease from their initial liver function determined by LiMAx. Liver regeneration assessed
functional recovery within 4 weeks in case of mild functional impairment after cessation of chemotherapy or within 8
weeks in case of major functional deterioration. Indocyanine plasma disappearance rate and biochemical parameters
remained stable or without a clear trend in case of minor functional impairment. This is the first report using a dynamic
liver function test to evaluate the impact and recovery from chemotherapy associated liver injury.
Conclusions: The LiMAx test might be a sensitive tool to diagnose mild functional impairment after chemotherapy
when standard liver function tests have remained within normal ranges and might be capable to assess the course of
regeneration after chemotherapy. This could be useful to optimize individual chemotherapy-free interval before liver
surgery can be carried out safely.
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Chemotherapy-induced liver injury (CALI) after receiving
potent chemotherapy is a considerable problem in patients
undergoing partial liver resection since increased peri-
operative mortality and morbidity have been reported
[1-3]. However patients presenting with multiple liver me-
tastasis frequently require preoperative chemotherapy to
downstage their initially unresectable disease [4-6]. In this
context oxaliplatin-based chemotherapeutic regimes – e.g.
FOLFOX or FOLFOXIRI – showed promising ability to
downstage spread and size but also increased perioperative
morbidity [3,7,8].
Whereas previous studies were based on the clinical
course and histology of resected liver parenchyma after* Correspondence: martin.stockmann@charite.de
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unless otherwise stated.surgery, less is known about the impact on actual liver
function and the course of regeneration after cessation
of chemotherapy [9,10].
Clinical biochemistry usually fail to diagnose reduced
liver function after neoadjuvant therapy as standard
parameters remain within normal ranges [11]. The
frequently applied indocyanine green plasma disappearance
rate test (ICG-PDR) also showed conflicting results
in predicting operative outcome after chemotherapy
[7,12-15].
Concerning the chemotherapy-free interval from cessa-
tion of chemotherapy to a safe partial liver resection only
statistical figures are known in the literature and suggest
an interval of six to eight weeks [16]. There is evidence
that vulnerability to especially oxaliplatin-based liver
injury might be different between patients. Thus an indi-
vidual time frame between chemotherapy and surgerytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be superior to a fixed interval [17,18].
Case presentation
Here we report two cases of patients that both received
adjuvant oxaliplatin-based chemotherapy as a conse-
quence of colorectal surgery due to adenocarcinoma. All
patients underwent assessment of liver function using
common biochemical liver tests, ICG-PDR and LiMAx
(maximum liver function capacity) test before, directly
after withdrawal as well as 4 and 8 weeks after cessation
of chemotherapy. Both patients did not have additional
regular drug intake during the study period and did not
suffer from any marked comorbidities known to impair
liver function.
LiMAx (maximum liver function capacity) reflects the
actual enzymatic liver function capacity. The test is
based on a bodyweight-adjusted intravenous 13C-labeled
methacetin bolus injection and continuous measurement
of 13CO2/
12CO2 concentration ratio using a special
device (FLIP, Humedics GmbH, Berlin, Germany) as
previously described by Stockmann and colleagues [19].
The LiMAx test (Figure 1) was developed and recently
introduced into clinical routine in our department
showing superior accuracy in diagnosing postoperative
liver failure and early graft dysfunction after liver trans-
plantation [19-21]. LiMAx values >315 μg/kg/h are
considered normal.
Indocyanine green plasma disappearance rate (ICG-
PDR) evaluates hepatic clearance and is suggested to
provide additional information on liver function. TheFigure 1 Concept of the LiMAx test. The figure is property of
Humedics GmbH (Berlin, Germany), the company marketing the
LiMAx test. The authors have the unrestricted permission to use the
figure for this publication.test is based on bodyweight-adjusted intravenous injection
of ICG followed by pulse spectrophotometry to assess
hepatic excretion via a special device (Dye Densitogram
Analyzer DDG2001, Nihon Khoden, Tokyo, Japan). ICG-
PDR is considered to be normal over 18%/min [22,23].
Case 1
Case 1 reports a 56-year-old male caucasian patient that
received 8 cycles of XELOX chemotherapy substituting
5-FU for the oral drug Xeloda. The patient started
XELOX chemotherapy with a LiMAx value of 463 μg/
kg/h and showed a decrease of functional liver capacity
by 56% to 204 μg/kg/h after withdrawal of chemother-
apy. ICG-PDR also declined from physiological 19.3%/
min prior to chemotherapy to 16.6%/min (Figure 2). In
terms of regeneration LiMAx indicates a continuous
course regaining liver function after a chemotherapy-
free interval of 8 weeks. In contrast ICG-PDR persisted
to decrease until 4 weeks after cessation of chemotherapy.
However it also restored its value by week 8. Biochemistry
showed a peak of serum bilirubin directly after chemo-
therapy and a temporary decrease in butyrylcholinesterase
(BChE) until 8 weeks after withdrawal of XELOX
(Table 1).
Case 2
Case 2 is a 68-year-old female caucasian patient that
underwent 12 cycles of FOLFOX4 chemotherapy. This
patient started chemotherapy with a LiMAx value of
488 μg/kg/h and showed a decrease of functional liver
capacity by 24% to 373 μg/kg/h after withdrawal of
chemotherapy. Four weeks after cessation of chemother-
apy initial liver function was regained and remained con-
stant during follow-up. ICG-PDR showed no clear trendFigure 2 Dynamic liver function assessment by LiMAx and
Indocyanine green plasma disappearance rate in Case 1.
Patients’ liver function capacity measured by LiMAx was reduced
by 56% after chemotherapy and ICG-PDR by 14%. Despite showing
a different course of regeneration, both dynamic liver function
tests indicate functional recovery within 8 weeks after cessation of
chemotherapy. pre-Chemo – prior to chemotherapy, post-Chemo –
after cessation of chemotherapy, 4 weeks – 4 weeks after cessation of
chemotherapy, 8 weeks – 8 weeks after cessation of chemotherapy.
Table 1 Liver function assessment of case 1
Laboratory parameters Reference range pre-Chemo post-Chemo 4 weeks 8 weeks
LiMAx (μg/kg/h) >315 468 203 390 495
ICG-PDR (%/min) >18 19.3 16.6 14 21.4
ALT (U/L) 10 - 50 41.00 33.00 34.00 41.00
Bilirubin (mg/dL) <1 0.6 2.15 1.08 1.03
INR 0,7 - 1,3 0.97 1.43 1.04 1.04
BChE (kU/L) >5.3 6.47 3.88 4.97 7.11
pre-Chemo – prior to chemotherapy, post-Chemo – after cessation of chemotherapy, 4 weeks – 4 weeks after cessation of Chemotherapy, 8 weeks – 8 weeks after
cessation of chemotherapy, LiMAx – Maximum liver function capacity, ICG-PDR, Indocyanine green plasma disappearance rate, ALT – Alanine transaminase, INR –
international normalized ratio, BChE – Butyrylcholinesterase.
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range (Figure 3). Biochemical liver parameters were also
within the reference ranges on each visit (Table 2).
Discussion
To our knowledge this is the first report using quanti-
tative liver function tests to assess deterioration and re-
generation of liver function duo to chemotherapy in
controlled prospective design with multiple testing. The
reported patients may be of interest as on patient
showed changes in common blood liver function tests
indicating marked impairment of liver function whereas
the other patient had no significant changes in standard
liver function tests.
In accordance with this observation both dynamic liver
function tests showed a major decrease in liver function
reaching pathological values in case 1 in comparisons to
case 2 where only a mild impairment of liver function
could be measured with the LiMAx test. LiMAx
indicates a defined course of regeneration in both cases
but a delay in case 1. ICG-PDR seems to be a good
indicator for regeneration in the case of majorFigure 3 Dynamic liver function assessment by LiMAx and
Indocyanine green plasma disappearance rate in Case 2.
Patients’ liver function capacity measured by LiMAx was reduced by
24% after chemotherapy. Four weeks after cessation of FOLFOX the
patient had already regained former liver function. ICG PDR showed
no clear trend. pre-Chemo – prior to chemotherapy, post-Chemo –
after cessation of chemotherapy, 4 weeks – 4 weeks after cessation of
chemotherapy, 8 weeks – 8 weeks after cessation of chemotherapy.impairment of liver function (case 1), however ICG-PDR
results in case 2 are inconclusive. This might be ex-
plained by general limitations of this testing procedure.
ICG-PDR is strongly dependent on blood flow to the
liver and the absence of cholestasis [24-26]. Since
damage to liver sinusoids accompanied with sinusoidal
obstruction is the basic pathological mechanism in
oxaliplatin-based liver injury it is debatable whether
ICG-PDR is a good indicator for liver function in this
explicit clinical situation [9,27]. The usefulness of
ICG-PDR after chemotherapy has already been ques-
tioned by Wakiya et al. [15].
Both LiMAx and ICG-PDR have shown superior prog-
nostic relevance for perioperative mortality and mor-
bidity in patients undergoing partial liver resection
compared to standard liver function tests [19,20,28,29].
Clinical decision trees exist for both testing procedures
allowing accurate risk stratification and prediction of
postoperative liver failure. The presented cases support
the hypothesis that regeneration of liver function has a
defined course, which is accessible by means of dynamic
liver functions tests which could be used to evaluate the
optimal chemotherapy-free interval prior to partial liver
resection using adequate decision algorithms [20,28].
In particular enzymatic based LiMAx test may also assess
mild impairment of liver function – which can contribute
to poorer postoperative outcome – providing additional
information compared to standard blood borne liver function
tests and ICG-PDR.
Certainly we present cases in patients without liver
metastases and without indication for liver surgery.
However our workgroup has already shown that the sole
presence of liver metastasis which is usually advanced in
patients that undergo neoadjuvant treatment can also
impair liver function making it impossible to discrimin-
ate between reduction of liver function by chemotherapy
or multiple metastasis in a proof of principle report [30].
Conclusions
This is the first report using a dynamic liver function
test in a controlled prospective setting to assess
Table 2 Liver function assessment of case 2
Laboratory parameters Reference range pre-Chemo post-Chemo 4 weeks 8 weeks
LiMAx (μg/kg/h) >315 488 373 481 487
ICG-PDR (%/min) >18 25.6 21.7 29.8 21.6
ALT (U/L) 7 - 35 13.00 26.00 17.00 21.00
Bilirubin (mg/dL) <1 0.27 0.62 0.56 0.39
INR 0,7 - 1,3 0.95 1.12 0.95 1.02
BChE (kU/L) >5.3 6.32 5.64 6.10 6.69
pre-Chemo – prior to chemotherapy, post-Chemo – after cessation of chemotherapy, 4 weeks – 4 weeks after cessation of Chemotherapy, 8 weeks – 8 weeks after
cessation of chemotherapy, LiMAx – Maximum liver function capacity, ICG-PDR, Indocyanine green plasma disappearance rate, ALT – Alanine transaminase, INR –
international normalized ratio, BChE – Butyrylcholinesterase.
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ment of liver function, which might not be recognised by
standard liver function tests and a defined course of regen-
eration after chemotherapy measurable with dynamic
liver function tests. This might help to optimize the
chemotherapy-free interval prior to liver surgery and
therefore needs to be addressed in a larger cohort.
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